Anthropic: Early Progress on Accelerating Drug Development with Claude

{
  "signal_id": "24f45628-418e-572b-01b2-55a5c0fb73a5",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-10-28T20:38:59+00:00",
  "company": {
    "name": "Anthropic",
    "domain": "anthropic.com"
  },
  "data": {
    "url": "https://www.hpcwire.com/aiwire/2026/10/28/anthropic-early-progress-on-accelerating-drug-development-with-claude/",
    "title": "Anthropic: Early Progress on Accelerating Drug Development with Claude - HPCwire",
    "excerpt": "Oct. 28, 2026 - Anthropic’s life sciences team is working to accelerate curing disease. Over the past several months, the company’s scientists have engaged in deep research partnerships with six organizations developing new medicines: BigHat Biosciences , Bristol Myers Squibb , Divergence Labs , Enveda , Generate Biomedicines , and The Column Group . Anthropic also has begun drug discovery efforts of its own. In doing so, the company has learned a lot about how Claude can support drug development, and how Anthropic will need to improve Claude further to realize AI’s potential in medicine. The company plans to scale this work up substantially. Credit: Anthropic There are many opportunities to speed up drug development, even beyond the most commonly discussed applications of AI, like proposing initial designs for new molecules. Developing a drug involves many varied tasks: doing early research to identify a target for a drug and the right type of drug to engage it, designing a molecule with the right properties, optimizing it to be manufactured reliably at scale, drafting the regulatory filings needed to run clinical trials, designing and administering those trials, and much more. Anthropic’s strategy to realize AI’s medical benefits is based on having AI increasingly involved in all of these tasks. There is no single problem to solve; the bottlenecks are distributed all...",
    "summary": "Anthropic partnered with Divergence Labs to use Claude for autonomous antibody design and hit generation targeting food allergies.",
    "planning": false,
    "image_url": "https://www.hpcwire.com/aiwire/wp-content/uploads/sites/3/2026/10/492ae2fdf955e71a24bfda5422f950febeeec07f-2000x1125-1-1024x576.png",
    "confidence": 0.95,
    "published_at": "2026-10-28T20:38:59Z",
    "article_sentence": "Over the past several months, the company’s scientists have engaged in deep research partnerships with six organizations developing new medicines: BigHat Biosciences , Bristol Myers Squibb , Divergence Labs , Enveda , Generate Biomedicines , and The Column Group .",
    "related_company_name": "Divergence Labs",
    "related_company_domain": "divergencelabs.com"
  }
}

curl https://signals.autobound.ai/v1/signals/24f45628-418e-572b-01b2-55a5c0fb73a5 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"anthropic.com","limit":20}'